S&P 500
Nasdaq
Dow Jones
NVDA
AAPL
TSLA
MSFT
BTC-USD
15-min delayed
Live
Home Market News Price Targets Penny Stocks Crypto Economy Commodities Education
Stocks About Contact

Immucell Corp

ICCC XNAS
$8.05 -0.27 (-3.19%) ▼ 15-min delayed
Open
$8.49
High
$8.65
Low
$7.97
Volume
23.2K
Market Cap
$72.83M

About Immucell Corp

ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.

Sector: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES Employees: 73 Website →

Key Financials

Period Revenue Net Income EPS
TTM 2025 $27.64M $-1,040,027 $-0.12
FY 2025 $27.64M $-1,040,027 $-0.12
Q3 2025 $5.51M $-139,748 $-0.02
Q2 2025 $6.44M $501.9K $0.06

Related Market News

No specific coverage for ICCC yet. Check out our latest market news or earnings calendar.

Get ICCC Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Immucell Corp.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.